Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited has announced four-year overall survival data from the ADCETRIS pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma . ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed in classical Hodgkin lymphoma and systemic ALCL, a type of T-cell lymphoma.